Arbutus Biopharma Corp
ABUS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.01B
Close$
$-2.94
157.5% downside
Current Fair Value
157.5% downsideOvervalued by 157.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.01 Billion |
|---|---|
| Enterprise Value | $992.74 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.17 |
| Beta | 0.62 |
| Outstanding Shares | 197,470,724 |
Return
| Return on Equity | 59.16% |
|---|---|
| Return on Assets | 55.85% |
| Return on Invested Capital | 54.56% |
Valuation & Multiples
| P/E Ratio | 6.48 |
|---|---|
| PEG | -2.13 |
| Price to Sales | - |
| Price to Book Ratio | 5.12 |
| Enterprise Value to Revenue | 5.46 |
| Enterprise Value to EBIT | 6.72 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$700,000
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$1.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9502▼ 13.94% |
|---|---|
| Total Calls | 186,600▼ 60.32% |
| Total Puts | 177,300▼ 65.40% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 72.29%▲ 0.56% |
|---|---|
| Total Invested | $866.51M▲ 38.55% |
| Investors Holding | 182▲ 7.00% |
ESG Score
No data
About Arbutus Biopharma Corp
CEO: William Collier